Cargando…
Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications
Synthetic oligodeoxynucleotides containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9). Our previous studies have shown the role of hydrogen-bond donor and acceptor groups of cytosine and guanine in the CpG motif and identified synthetic immunostimulatory motifs. In the present stud...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904100/ https://www.ncbi.nlm.nih.gov/pubmed/16798912 http://dx.doi.org/10.1093/nar/gkl430 |
_version_ | 1782133961329213440 |
---|---|
author | Putta, Mallikarjuna Reddy Zhu, FuGang Li, Yukui Bhagat, Lakshmi Cong, YanPing Kandimalla, Ekambar R. Agrawal, Sudhir |
author_facet | Putta, Mallikarjuna Reddy Zhu, FuGang Li, Yukui Bhagat, Lakshmi Cong, YanPing Kandimalla, Ekambar R. Agrawal, Sudhir |
author_sort | Putta, Mallikarjuna Reddy |
collection | PubMed |
description | Synthetic oligodeoxynucleotides containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9). Our previous studies have shown the role of hydrogen-bond donor and acceptor groups of cytosine and guanine in the CpG motif and identified synthetic immunostimulatory motifs. In the present study to elucidate the significance of N3-position of cytosine and N1-position of guanine in the CpG motif, we substituted C or G of a CpG dinucleotide with N(3)-Me-cytosine or N(1)-Me-guanine, respectively, in immunomodulatory oligodeoxynucleotides (IMOs). IMOs containing N-Me-cytosine or N-Me-guanine in C- or G-position, respectively, of the CpG dinucleotide showed activation of HEK293 cells expressing TLR9, but not TLR3, 7 or 8. IMOs containing N-Me-cytosine or N-Me-guanine modification showed activity in mouse spleen cell cultures, in vivo in mice, and in human cell cultures. In addition, IMOs containing N-Me-substitutions reversed antigen-induced Th2 immune responses towards a Th1-type in OVA-sensitized mouse spleen cell cultures. These studies suggest that TLR9 tolerates a methyl group at N1-position of G and a methyl group at N3-position of C may interfere with TLR9 activation to some extent. These are the first studies elucidating the role of N3-position of cytosine and N1-position of guanine in a CpG motif for TLR9 activation and immune stimulation. |
format | Text |
id | pubmed-1904100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-19041002007-06-28 Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications Putta, Mallikarjuna Reddy Zhu, FuGang Li, Yukui Bhagat, Lakshmi Cong, YanPing Kandimalla, Ekambar R. Agrawal, Sudhir Nucleic Acids Res Article Synthetic oligodeoxynucleotides containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9). Our previous studies have shown the role of hydrogen-bond donor and acceptor groups of cytosine and guanine in the CpG motif and identified synthetic immunostimulatory motifs. In the present study to elucidate the significance of N3-position of cytosine and N1-position of guanine in the CpG motif, we substituted C or G of a CpG dinucleotide with N(3)-Me-cytosine or N(1)-Me-guanine, respectively, in immunomodulatory oligodeoxynucleotides (IMOs). IMOs containing N-Me-cytosine or N-Me-guanine in C- or G-position, respectively, of the CpG dinucleotide showed activation of HEK293 cells expressing TLR9, but not TLR3, 7 or 8. IMOs containing N-Me-cytosine or N-Me-guanine modification showed activity in mouse spleen cell cultures, in vivo in mice, and in human cell cultures. In addition, IMOs containing N-Me-substitutions reversed antigen-induced Th2 immune responses towards a Th1-type in OVA-sensitized mouse spleen cell cultures. These studies suggest that TLR9 tolerates a methyl group at N1-position of G and a methyl group at N3-position of C may interfere with TLR9 activation to some extent. These are the first studies elucidating the role of N3-position of cytosine and N1-position of guanine in a CpG motif for TLR9 activation and immune stimulation. Oxford University Press 2006 2006-06-23 /pmc/articles/PMC1904100/ /pubmed/16798912 http://dx.doi.org/10.1093/nar/gkl430 Text en © 2006 The Author(s) |
spellingShingle | Article Putta, Mallikarjuna Reddy Zhu, FuGang Li, Yukui Bhagat, Lakshmi Cong, YanPing Kandimalla, Ekambar R. Agrawal, Sudhir Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications |
title | Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications |
title_full | Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications |
title_fullStr | Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications |
title_full_unstemmed | Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications |
title_short | Novel oligodeoxynucleotide agonists of TLR9 containing N(3)-Me-dC or N(1)-Me-dG modifications |
title_sort | novel oligodeoxynucleotide agonists of tlr9 containing n(3)-me-dc or n(1)-me-dg modifications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904100/ https://www.ncbi.nlm.nih.gov/pubmed/16798912 http://dx.doi.org/10.1093/nar/gkl430 |
work_keys_str_mv | AT puttamallikarjunareddy noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications AT zhufugang noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications AT liyukui noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications AT bhagatlakshmi noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications AT congyanping noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications AT kandimallaekambarr noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications AT agrawalsudhir noveloligodeoxynucleotideagonistsoftlr9containingn3medcorn1medgmodifications |